22 relations: Anorectic, Anti-obesity medication, Body mass index, Cannabinoid receptor type 1, Committee for Medicinal Products for Human Use, CYP3A4, Diabetes mellitus, Drug development, Drug discovery, Dyslipidemia, European Commission, European Medicines Agency, Food and Drug Administration, Gastroenteritis, Inverse agonist, Kidney, Liver, Postmarketing surveillance, Receptor (biochemistry), Risk–benefit ratio, Sanofi, Therapeutic index.
An anorectic or anorexic is a drug which reduces appetite, resulting in lower food consumption, leading to weight loss.
Anti-obesity medication or weight loss drugs are pharmacological agents that reduce or control weight.
The body mass index (BMI) or Quetelet index is a value derived from the mass (weight) and height of an individual.
The cannabinoid type 1 receptor, often abbreviated as CB1, is a G protein-coupled cannabinoid receptor located in the central and peripheral nervous system.
The Committee for Medicinal Products for Human Use (CHMP), formerly known as Committee for Proprietary Medicinal Products (CPMP), is the European Medicines Agency's committee responsible for elaborating the agency's opinions on all issues regarding medicinal products for human use.
Cytochrome P450 3A4 (abbreviated CYP3A4) is an important enzyme in the body, mainly found in the liver and in the intestine.
Diabetes mellitus (DM), commonly referred to as diabetes, is a group of metabolic disorders in which there are high blood sugar levels over a prolonged period.
Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery.
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood.
The European Commission (EC) is an institution of the European Union, responsible for proposing legislation, implementing decisions, upholding the EU treaties and managing the day-to-day business of the EU.
The European Medicines Agency (EMA) is a European Union agency for the evaluation of medicinal products.
The Food and Drug Administration (FDA or USFDA) is a federal agency of the United States Department of Health and Human Services, one of the United States federal executive departments.
Gastroenteritis, also known as infectious diarrhea, is inflammation of the gastrointestinal tract -- the stomach and small intestine.
In the field of pharmacology, an inverse agonist is an agent that binds to the same receptor as an agonist but induces a pharmacological response opposite to that agonist.
The kidneys are two bean-shaped organs present in left and right sides of the body in vertebrates.
The liver, an organ only found in vertebrates, detoxifies various metabolites, synthesizes proteins, and produces biochemicals necessary for digestion.
Postmarketing surveillance (PMS) (also post market surveillance) is the practice of monitoring the safety of a pharmaceutical drug or medical device after it has been released on the market and is an important part of the science of pharmacovigilance.
In biochemistry and pharmacology, a receptor is a protein molecule that receives chemical signals from outside a cell.
A risk–benefit ratio is the ratio of the risk of an action to its potential benefits.
Sanofi S.A. is a French multinational pharmaceutical company headquartered in Gentilly, France, as of 2013 the world's fifth-largest by prescription sales.
The therapeutic index (TI; also referred to as therapeutic ratio) is a comparison of the amount of a therapeutic agent that causes the therapeutic effect to the amount that causes toxicity.